These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12742493)

  • 1. Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty.
    Tedesco Silva H; Felipe CR; Machado PG; Garcia R; Motegi S; Hosaka BH; Hanzawa NM; Park SI; Casarini D; Lima VC; Franco M; Medina-Pestana JO
    Transplant Proc; 2003 May; 35(3 Suppl):177S-180S. PubMed ID: 12742493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.
    Machado PG; Felipe CR; Hanzawa NM; Park SI; Garcia R; Alfieri F; Franco M; Silva HT; Medina-Pestana JO
    Clin Transplant; 2004 Feb; 18(1):28-38. PubMed ID: 15108768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.
    MacDonald AS;
    Transplantation; 2001 Jan; 71(2):271-80. PubMed ID: 11213073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
    Kahan BD; Julian BA; Pescovitz MD; Vanrenterghem Y; Neylan J
    Transplantation; 1999 Nov; 68(10):1526-32. PubMed ID: 10589950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients-preliminary results.
    Machado PG; Garcia C; Felipe CR; Garcia R; Franco M; Delcelo R; Silva HT; Medina JO
    Transplant Proc; 2001; 33(1-2):1074-5. PubMed ID: 11267196
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
    Tedesco-Silva H; Garcia VD; Contieri FL; De Boni Monteiro de Carvalho D; Noronha IL; Gonçalves RT; de Paula FJ; Abbud-Filho M; Manfro RC; David-Neto E; Alfieri F; Ikehara E; Jiang Q; Tai SS; Medina-Pestana JO
    Transplant Proc; 2010 Jun; 42(5):1659-66. PubMed ID: 20620495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
    Keogh A; Richardson M; Ruygrok P; Spratt P; Galbraith A; O'Driscoll G; Macdonald P; Esmore D; Muller D; Faddy S
    Circulation; 2004 Oct; 110(17):2694-700. PubMed ID: 15262845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
    Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.
    Kahan BD
    Lancet; 2000 Jul; 356(9225):194-202. PubMed ID: 10963197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.
    Liu KL; Chu SH; Chiang YJ; Wu CT; Chen Y
    Transplant Proc; 2004 Sep; 36(7):2051-2. PubMed ID: 15518742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results.
    Ferreira AN; Machado PG; Felipe CR; Motegi SA; Hosaka BH; Tanaka MK; Kamura LA; Park SI; Garcia R; Franco M; Alfieri F; Casarini DE; Tedesco-Silva H; Medina-Pestana JO
    Clin Transplant; 2005 Oct; 19(5):607-15. PubMed ID: 16146551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo sirolimus-based regimen in Thai renal transplant recipients.
    Townamchai N; Avihingsanon Y; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
    Transplant Proc; 2008 Sep; 40(7):2206-8. PubMed ID: 18790193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB; Grimm EM
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients.
    Morrisett JD; Abdel-Fattah G; Kahan BD
    Transplant Proc; 2003 May; 35(3 Suppl):143S-150S. PubMed ID: 12742487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.